Involving A Modified Enzyme (e.g., Abzyme, Recombinant, Chemically Altered, Etc.) Patents (Class 435/7.6)
  • Patent number: 6406862
    Abstract: A C-reactive protein concentration level test and kit for on-site determination of C-reactive protein levels in biological samples is disclosed.
    Type: Grant
    Filed: October 6, 1999
    Date of Patent: June 18, 2002
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventor: Teresa Krakauer
  • Patent number: 6365358
    Abstract: The invention provides a human ubiquitin-like conjugating protein (UBCLE) and polynucleotides which identify and encode UBCLE. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of UBCLE.
    Type: Grant
    Filed: June 9, 1999
    Date of Patent: April 2, 2002
    Assignee: Incyte Genomics, Inc.
    Inventors: Jennifer L. Hillman, Purvi Shah, Neil C. Corley
  • Publication number: 20020034797
    Abstract: Combinatorial libraries of polyketides can be obtained by suitable manipulation of a host modular polyketide synthase gene cluster such as that which encodes the PKS for erythromycin. The combinatorial library is useful as a source of pharmaceutically active compounds.
    Type: Application
    Filed: April 30, 1997
    Publication date: March 21, 2002
    Inventors: CHAITAN KHOSLA, GARY ASHLEY, HONG FU, CAMILLA M. KAO, ROBERT MCDANIEL
  • Patent number: 6342365
    Abstract: Substantially pure glycosidases capable for cleaving selected glycosidic bonds have been described including glycosidases isolated from Xanthomonas and recombinant glycosidases. Substrate specificity of isolated enzymes have been identified for GlcNac&bgr;1-X, Gal&agr;1-3R, Gal&agr;1-6R, Gal&bgr;1-3R, Fuc&agr;1-2R, Fuc&agr;1-3R, Fuc&agr;1-4R, Man&agr;1-2R, Man&agr;1-3R, Man&agr;1-6R, Man&bgr;1-4R, Xyl&bgr;1-2R, Glc&bgr;1-4R, and Gal&bgr;1-4R providing improved capability for selectively cleaving a glycosidic linkage in a carbohydrate substrate and for forming modified carbohydrates.
    Type: Grant
    Filed: February 24, 1999
    Date of Patent: January 29, 2002
    Assignee: New England Biolabs, Inc.
    Inventors: Sharon T. Wong-Madden, Ellen P. Guthrie, David Landry, Christopher H. Taron, Chudi Guan, Phillips W. Robbins
  • Patent number: 6333154
    Abstract: A signal amplification system comprises a bacterial multi-hybrid system, and more preferably a two-hybrid system, of at least two chimeric polypeptides containing a first chimeric polypeptide corresponding to a first fragment of an enzyme and a second chimeric polypeptide corresponding to a second fragment of an enzyme or a modulating substance capable of activating said enzyme. The first fragment is fused to a molecule of interest and the second fragment or the modulating substance is fused to a target ligand. The activity of the enzyme is restored by the in vivo interaction between the molecule of interest and the target ligand. Signal amplification is generated and, for example, triggers transcriptional activation. The signal amplification system is useful in a method of selecting a molecule of interest, which is capable of binding to target ligand, wherein the interaction between the molecule of interest and the target ligand is detected with the signal amplification system as a kit therefor.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: December 25, 2001
    Assignee: Institut Pasteur
    Inventors: Daniel Ladant, Gouzel Karimova, Agnes Ullmann
  • Patent number: 6329160
    Abstract: A genetic construct for use in a biosensor comprising: (a) a first nucleic acid molecule including a sequence encoding a reporter molecule having a detectable activity; and (b) a second nucleic acid molecule including a sequence encoding an enzyme which produces a substrate for the reporter molecule, the first sequence being under the control of a first inducible promoter and the second sequence being under the control of a second inducible promoter. A biosensor for measuring an environmental signal comprising a cell including the genetic construct and a means for measuring the activity of the reporter molecule in the cell when the cell has been exposed to the environmental signal.
    Type: Grant
    Filed: September 7, 1999
    Date of Patent: December 11, 2001
    Assignee: CRC for Waste Management and Pollution Control Limited
    Inventors: Rene Schneider, Tony Vancov, Karen Jury
  • Patent number: 6296853
    Abstract: E6-BP polypeptide, nucleic acids encoding E6-BP polypeptides, and uses thereof.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: October 2, 2001
    Assignee: New England Medical Center Hospitals, Inc.
    Inventors: Elliot J. Androphy, Jason J. Chen
  • Patent number: 6297013
    Abstract: This invention provides plasmids that are useful in detecting and determining the DNA-binding activity of sequence-specific DNA-binding molecules. The invention further provides plasmids that are useful in detecting and determining the activity of KNA polymerases in initiating transcription. In particular, the invention relates to plasmids that contain unique restriction sites and cognate nucleotide recognition sequences for sequence-specific DNA-binding molecules. Also provided are methods for using the plasmids disclosed herein.
    Type: Grant
    Filed: June 24, 1999
    Date of Patent: October 2, 2001
    Assignee: Dnab Diagnostics Inc.
    Inventors: Antony R. Morgan, Alberto Severini
  • Patent number: 6290966
    Abstract: Disclosed are novel recombinant mutant strains of mycobacteria that are deficient for the synthesis or transport of dimycoserosalphthiocerol (“DIM”). The present invention also provides a method of producing a recombinant mutant mycobacterium that is deficient for the synthesis or transport of DIM, comprising mutating a nucleic acid responsible for the synthesis or transport of dimycoserosalphthiocerol, including a nucleic acid comprising the promoter for the pps operon, fadD28 or mmpL7. The present invention also provides a vaccine comprising a DIM mutant mycobacterium of the present invention, as well as a method for the treatment or prevention of tuberculosis in a subject using the vaccine.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: September 18, 2001
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Jeffery S. Cox, William R. Jacobs, Jr.
  • Patent number: 6287785
    Abstract: An improved homogeneous enzyme immunoassay process for quantitatively analyzing an antigen by determining the change in the enzymatic activity caused by a reaction between the antigen and an enzyme-labeled antibody. The antigen is reacted with an enzyme-labeled antibody, followed by the reaction with a second antibody capable of recognizing and binding to a different epitope and then with a third antibody capable of recognizing and binding to the second antibody. The enzymatic activity of the labeling enzyme is determined by a water-insoluble substrate. Using the water-insoluble substrate, steric hindrance is enhanced. A highly-sensitive analysis can be carried out by a simple operation even when the antigen has a molecular weight falling within an intermediate range, for example, a range of M.W. 10,000 to 70,000.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 11, 2001
    Assignee: Fuji Photo Film Co., Ltd.
    Inventors: Hiroshi Shinoki, Osamu Seshimoto
  • Publication number: 20010018200
    Abstract: The present invention relates to a chemically modified mutant protein including a cysteine residue substituted for a residue other than cysteine in a precursor protein, the substituted cysteine residue being subsequently modified by reacting the cysteine residue with a glycosylated thiosulfonate. Also, a method of producing the chemically modified mutant protein is provided. The present invention also relates to a glycosylated methanethiosulfonate. Another aspect of the present invention is a method of modifying the functional characteristics of a protein including providing a protein and reacting the protein with a glycosylated methanethiosulfonate reagent under conditions effective to produce a glycoprotein with altered functional characteristics as compared to the protein. In addition, the present invention relates to methods of determining the structure-function relationships of chemically modified mutant proteins.
    Type: Application
    Filed: July 2, 1999
    Publication date: August 30, 2001
    Inventors: BRYAN J. JONES, BENJAMIN G. DAVIS
  • Patent number: 6277586
    Abstract: The invention provides cDNA molecules comprising a part of the cDNA sequence of GAD65 which encode at least one epitope for autoantibodies to GAD65. The invention also provides cloning vehicles capable of replication and expression comprising cDNA molecules coding for GAD65. The invention further provides for hosts transformed with a vehicle having a cDNA molecule coding for GAD65. In another embodiment, the invention provides for the detection of autoantibodies to GAD65 using the GAD65 polypeptides coded for by the cDNA molecules of the invention.
    Type: Grant
    Filed: August 11, 1999
    Date of Patent: August 21, 2001
    Assignee: Regents of the University of California
    Inventors: Allan J. Tobin, Mark G. Erlander, Daniel L. Kaufman
  • Patent number: 6274318
    Abstract: The invention provides an isolated gene encoding Mch6 as well as functional fragments thereof. Also provided are isolated nucleic acid sequences encoding Mch6 or functional fragments thereof. The gene or nucleic acid sequences can be single or double stranded nucleic acids corresponding to coding or non-coding strands of the Mch6 nucleotide sequences. The invention further provides an isolated Mch6 polypeptide and isolated large and small subunits of the Mch6 polypeptide, including functional fragments thereof.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: August 14, 2001
    Assignee: Thomas Jefferson University
    Inventors: Emad S. Alnemri, Teresa Fernandes-Alnemri, Gerald Litwack
  • Patent number: 6268123
    Abstract: The present invention relates to processes for the direct detection of biochemically functional retroviruses in biological samples. The processes of the invention are characterized by the structure-specific extraction of retrovirus particles and a subsequent analysis and detection of retrovirus-specific enzymatic reactions. The processes of the invention have broad application in the diagnosis of retroviral infection and virological research.
    Type: Grant
    Filed: February 28, 1996
    Date of Patent: July 31, 2001
    Assignee: Retro-Tech GmbH
    Inventor: Ortwin Faff
  • Patent number: 6262265
    Abstract: Novel chemical analogs are disclosed for the essential heroin metabolite 6-O-acetyl morphine (6MAM). The analogs optionally can be made to contain protein reactive groups, and can be used to form protein conjugates, fluorescently labeled compounds, and solid-phase adsorbants. The proteins conjugates can be used in turn to raise antibodies reactive with 6MAM and having a low cross-reactivity with the closely related opiates, morphine and codeine. The antibodies can be used in combination with labeled analogs in exquisitely sensitive immunoassays suitable for testing for heroin abuse.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: July 17, 2001
    Assignee: Microgenics Corporation
    Inventors: Riaz Rouhani, Gerald F. Sigler
  • Patent number: 6248229
    Abstract: The invention relates to novel methods and compositions for the detection of analytes using the nuclear reorganization energy, &lgr;, of an electron transfer process.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: June 19, 2001
    Assignee: Clinical Micro Sensors, Inc.
    Inventor: Thomas J. Meade
  • Patent number: 6229001
    Abstract: The invention relates to the nucleic acid sequence and amino acid sequence of dihydrofolate reductase (DHFR) from mycobacteria and to expression of recombinant DHFR protein. Utilizing the recombinant protein, novel therapies and diagnostic strategies can be developed and selective antimycobacterial compositions can be designed and utilized to treat mycobacterial infections in patients. This invention includes all or portions of novel recombinant nucleic acids encoding DHFR for mycobacteria such as M. avium, to novel recombinant DHFR peptides produced by such sequences, and to vaccines, diagnostic kits, cells and therapies utilizing these peptides and nucleic acid sequences. The present invention relates to methods for using the sequences of the present invention to develop drugs specific to M. avium and other mycobacteria, to identify and sequence corresponding sequences in species other than M. avium, as well as diagnostic and treatment methods incorporating the disclosed sequences and peptides.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: May 8, 2001
    Assignee: Southern Research Institute
    Inventors: William W. Barrow, Sabrina Z. Van Ginkel, Thomas P. Dooley, William J. Suling
  • Patent number: 6221617
    Abstract: A method and recombinant assay cell for detecting growth hormone releasing hormone (GHRH) in a sample, the method includes exposing a recombinant cell to the sample and measuring transcription of a reporter gene. A suitable recombinant cell includes a reporter gene operatively connected to a cAMP-responsive promoter and a GHRH-responsive protein whose binding to GHRH induces the production of cAMP. GHRH present in an assay sample results in the GHRH-responsive protein activating the production of cAMP, which then activates the c-AMP-responsive promoter to express the reporter protein. The amount of reporter protein produced is quantitatively correlated to the amount of GHRH in the sample. In one embodiment, the protein is a cell surface receptor for GHRH.
    Type: Grant
    Filed: December 5, 1997
    Date of Patent: April 24, 2001
    Inventors: Julie Heinrich, H. Edward Grotjan, Fred W. Wagner, Yuannan Xia
  • Patent number: 6217864
    Abstract: A method for in vivo selective targeted degradation of intracellular proteins in situ by inducing in vivo or ex vivo in cells a production of dual-function protein comprising N-terminal domain as well as a C-terminal domain or delivering the dual-function protein. The N-terminal domain of the dual-function protein destabilizes the target protein and directs its degradation when linked to it through a linker between the target protein and between the protein agent of the invention. The protein degradation directing N-terminal domain is a subregion within the first 97 amino acids corresponding to the N-terminus of protein antizyme.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: April 17, 2001
    Assignee: The Regents of the University of California
    Inventors: Philip Coffino, Xianqiang Li
  • Patent number: 6207396
    Abstract: To improve the detection of LSD in biological samples, antibodies are raised to LSD conjugated to a protein carrier, preferably through the indole ring. Selected antibodies are matched with an immunoassay reagent in which the LSD is conjugated in the same position to a labeling or separation means. The set of reagents can be used in immunoassays with remarkably little cross-reactivity with potential interfering substances such as chlorpromazine and ergotamine, and a low false-positive rate in a panel of clinical test samples. Also provided is a set of reagents for measuring glucuronide metabolites of LSD by immunoassay, which permits exposure to LSD to be determined over a longer diagnostic window.
    Type: Grant
    Filed: February 20, 1998
    Date of Patent: March 27, 2001
    Assignee: Microgenics Corporation
    Inventors: Gerald F. Sigler, Riaz Rouhani, David Davoudzadeh, William A. Coty, Jeffrey E. Shindelman, Paul R. Morrill
  • Patent number: 6203986
    Abstract: A method for visualizing the location and movement of a specific RNA of interest in a living cell, in real time, is disclosed. The method includes the following steps: (a) providing a DNA encoding the RNA, which RNA includes a protein-binding site; (b) providing a nucleic acid encoding a fusion protein, which fusion protein comprises a fluorescent domain and an RNA-binding domain; (c) introducing the DNA encoding the RNA, and the nucleic acid encoding the fusion protein, into a eukaryotic cell so that the DNA encoding the RNA and the nucleic acid encoding the fusion protein are expressed in the cell; and (d) detecting fluorescence outside the nucleus or inside the nucleus of the cell, with the fluorescence being from the fusion protein bound to the RNA. In some embodiments, the fusion protein also includes an intracellular localization domain.
    Type: Grant
    Filed: October 22, 1998
    Date of Patent: March 20, 2001
    Inventors: Robert H. Singer, Edouard Bertrand
  • Patent number: 6203994
    Abstract: The invention relates to novel fluorescence-based assays for protein kinases and phosphatases which can be used in high throughput screening. The methods of the invention utilize a competitive immunoassay to determine the amount of substrate that is phosphorylated or dephosphorylated during the course of a kinase or phosphatase reaction to yield a product, as well as the phosphorylating or dephosphorylating activity of a kinase or phosphatase.
    Type: Grant
    Filed: December 2, 1998
    Date of Patent: March 20, 2001
    Assignee: Pharmacia & Upjohn Company
    Inventors: Dennis E. Epps, Charles K. Marschke
  • Patent number: 6194183
    Abstract: The invention relates to a method of identifying enzymes suitable for use in detergents, especially the selection of specific enzyme variants among a large number of such variants created through random mutagenesis.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: February 27, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Peter Markvardsen, Mads Eskelund Bjornvad, Frank Mikkelsen, Borge Diderichsen
  • Patent number: 6190916
    Abstract: The present invention relates to stable compositions useful as primary standards and calibrators and controls comprising a cardiac troponin I (cTnI) such as native, recombinant, addition and deletion forms thereof, whether or not complexed with other troponin subunits such as TnC and/or TnT, in an inactivated human serum. The compositions are obtained by incubating troponin complexes with human serum. The compositions are characterized by an immunodetectability ratio of epitopes on the N-terminal segment to epitopes on the C-terminal segment substantially equivalent to that of pooled, fresh serum from acute myocardial infarction patients.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: February 20, 2001
    Assignee: Spectral Diagnostics, Inc.
    Inventors: Shigui Liu, Min Yuan Zhang, Qinwei Shi
  • Patent number: 6177241
    Abstract: This invention provides a method, a reagent, and a kit for detecting herpesvirus-specific IgM antibodies indicative of recent infection while preventing detection of low levels of herpesvirus-specific IgM antibodies present in individuals of low risk. The invention also provides a reagent for use in detecting herpesvirus-specific IgM antibodies indicative of recent infection while preventing detection of low levels of herpesvirus-specific IgM antibodies present in individuals of low risk.
    Type: Grant
    Filed: September 22, 1997
    Date of Patent: January 23, 2001
    Assignee: Abbott Laboratories
    Inventor: Gregory T. Maine
  • Patent number: 6171820
    Abstract: Disclosed is a rapid and facilitated method of producing from a parental template polynucleotide, a set of mutagenized progeny polynucleotides whereby at each original codon position there is produced at least one substitute codon encoding each of the 20 naturally encoded amino acids. Accordingly, there is also provided a method of producing from a parental template polypeptide, a set of mutagenized progeny polypeptides wherein each of the 20 naturally encoded amino acids is represented at each original amino acid position. The method provided is termed site-saturation mutagenesis, or simply saturation mutagenesis, and can be used in combination with other mutagenization processes, such as, for example, a process wherein two or more related polynucleotides are introduced into a suitable host cell such that a hybrid polynucleotide is generated by recombination and reductive reassortment.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: January 9, 2001
    Assignee: Diversa Corporation
    Inventor: Jay M. Short